Arovella Therapeutics Limited announced the appointment of Tim Luscombe as Chief Financial Officer (CFO), effective 1 December 2023. Tim replaces Mr. Phillip Hains, who has been the CFO since 1 July 2020. Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the Healthcare sector.

Tim has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad. He currently serves as a CFO and Company Secretary for several ASX listed, public unlisted and private Healthcare companies. Tim holds a Bachelor of Commerce from the University of Melbourne and a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

This appointment follows the resignation of Mr. Phillip Hains as CFO, effective 1 December 2023.